Cargando…

Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma

BACKGROUND: The variable prognosis in stage III cutaneous melanoma is partially due to unknown prognostic factors. Improved prognostic tools are required to define patients with an increased risk of developing metastatic disease who might benefit from adjuvant therapies. The aim was to examine if ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Falkenius, Johan, Johansson, Hemming, Tuominen, Rainer, Frostvik Stolt, Marianne, Hansson, Johan, Egyhazi Brage, Suzanne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5576332/ https://www.ncbi.nlm.nih.gov/pubmed/28851300 http://dx.doi.org/10.1186/s12885-017-3577-x

Ejemplares similares

Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells
por: Azimi, Alireza, et al.
Publicado: (2017)

Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status
por: Das, Ishani, et al.
Publicado: (2019)

PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma
por: Vidarsdottir, Linda, et al.
Publicado: (2021)

Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance
por: Azimi, A, et al.
Publicado: (2014)

Metabolic markers GAPDH, PKM2, ATP5B and BEC-index in advanced serous ovarian cancer
por: Hjerpe, Elisabet, et al.
Publicado: (2013)

Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma
por: Das, Ishani, et al.
Publicado: (2020)

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
por: Azimi, Alireza, et al.
Publicado: (2018)

AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma
por: Das, Ishani, et al.
Publicado: (2020)

Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastastic cutaneous malignant melanoma
por: Svedman, Fernanda Costa, et al.
Publicado: (2018)

Proliferation and Immune Response Gene Signatures Associated with Clinical Outcome to Immunotherapy and Targeted Therapy in Metastatic Cutaneous Malignant Melanoma
por: Costa Svedman, Fernanda, et al.
Publicado: (2022)

Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib
por: Vidarsdottir, Linda, et al.
Publicado: (2020)

ΔNp73 regulates the expression of the multidrug-resistance genes ABCB1 and ABCB5 in breast cancer and melanoma cells - a short report
por: Sakil, Habib A. M., et al.
Publicado: (2017)

The Driverless Triple-Wild-Type (BRAF, RAS, KIT) Cutaneous Melanoma: Whole Genome Sequencing Discoveries
por: Pipek, Orsolya, et al.
Publicado: (2023)

Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas
por: Edmunds, S C, et al.
Publicado: (2003)

O6-methylguanine-DNA methyltransferase activities in biopsies of human melanoma tumours.
por: Egyházi, S., et al.
Publicado: (1995)

Ubiquitination and adaptive responses to BRAF inhibitors in Melanoma
por: Saei, Azad, et al.
Publicado: (2018)

Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival
por: Tobin, N. P., et al.
Publicado: (2015)

A novel 7 RNA-based signature for prediction of prognosis and therapeutic responses of wild-type BRAF cutaneous melanoma
por: Sun, Ruizheng, et al.
Publicado: (2022)

Adaptive Responses as Mechanisms of Resistance to BRAF Inhibitors in Melanoma
por: Saei, Azad, et al.
Publicado: (2019)

Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study
por: Helgadottir, Hildur, et al.
Publicado: (2023)

Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature
por: Gençler, Bilgen, et al.
Publicado: (2016)

Defining the Criteria for Reflex Testing for BRAF Mutations in Cutaneous Melanoma Patients
por: Zhou, Sarah, et al.
Publicado: (2021)

Autophagy in BRAF-mutant cutaneous melanoma: recent advances and therapeutic perspective
por: Fratta, Elisabetta, et al.
Publicado: (2023)

Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma
por: Nepote, Alessandro, et al.
Publicado: (2022)

BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib
por: Ranzani, Marco, et al.
Publicado: (2015)

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma
por: Robert, Caroline, et al.
Publicado: (2020)

The Transcriptional Landscape of BRAF Wild Type Metastatic Melanoma: A Pilot Study
por: Lastraioli, Elena, et al.
Publicado: (2022)

Ablation of sensory nerves favours melanoma progression
por: Prazeres, Pedro H. D. M., et al.
Publicado: (2020)

High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families
por: Helgadottir, Hildur, et al.
Publicado: (2014)

Epigenetic Changes of EGFR play an important role in BRAF inhibitor Resistant Cutaneous Melanomas
por: Wang, Jinhua, et al.
Publicado: (2014)

Quality of Life in the First Year of Follow-Up in a Randomized Multicenter Trial Assessing the Role of Imaging after Radical Surgery of Stage IIB-C and III Cutaneous Melanoma (TRIM Study)
por: Naeser, Ylva, et al.
Publicado: (2022)

Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe – a systematic review of the literature
por: Svedman, Fernanda Costa, et al.
Publicado: (2016)

Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib
por: Nowara, Elzbieta, et al.
Publicado: (2016)

Plasma proteome alterations by MAPK inhibitors in BRAF(V600)-mutated metastatic cutaneous melanoma()()
por: Babačić, Haris, et al.
Publicado: (2021)

BRAF V600E Immunohistochemistry Predicts Prognosis of Patients with Cutaneous Melanoma in Thai population
por: Meevassana, Jiraroch, et al.
Publicado: (2022)

Prenylation Inhibition-Induced Cell Death in Melanoma: Reduced Sensitivity in BRAF Mutant/PTEN Wild-Type Melanoma Cells
por: Garay, Tamás, et al.
Publicado: (2015)

The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy
por: Hannan, Enda J., et al.
Publicado: (2017)

Immunometabolic Network Interactions of the Kynurenine Pathway in Cutaneous Malignant Melanoma
por: Rad Pour, Soudabeh, et al.
Publicado: (2020)

Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma
por: Tahiri, Andliena, et al.
Publicado: (2013)

Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanoma
por: Dummer, Reinhard, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_j5rsj07hhrn6aqhhjhc5n5fecj